{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:40:30Z","timestamp":1791574830600,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40290-024-00524-z","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T02:01:18Z","timestamp":1714960878000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria"],"prefix":"10.1007","volume":"38","author":[{"given":"Uchenna Geraldine","family":"Elemuwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraden","family":"Bitrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-448X","authenticated-orcid":false,"given":"Ibrahim Adekunle","family":"Oreagba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline Ijeoma","family":"Osakwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola Sadikat","family":"Abiodun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Onu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmau","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela E.","family":"Faniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Etuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rametu","family":"Momodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana Mojisola","family":"Adeyeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"524_CR1","unstructured":"World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions (WHO\/EDM\/QSM\/2002.2). Geneva: World Health Organization; 2002."},{"key":"524_CR2","unstructured":"Federal Ministry of Health. Nigerian National Pharmacovigilance Policy and Implementation Framework. 2020. https:\/\/msh.org\/wp-content\/uploads\/2021\/03\/nigerian_national_pharmacogilance_policy_implementation_framework.pdf. Accessed 10 July 2023."},{"key":"524_CR3","unstructured":"World Health Organization. WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems (ISBN 9789241508254). https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/186642\/9789241508254_eng.pdf. Accessed 10 July 2023."},{"issue":"1","key":"524_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12911-022-01832-7","volume":"22","author":"A Fukushima","year":"2022","unstructured":"Fukushima A, Iessa N, Balakrishnan MR, et al. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. BMC Med Inform Decis Mak. 2022;22(1):118. https:\/\/doi.org\/10.1186\/s12911-022-01832-7.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"41 Suppl","key":"524_CR5","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.1016\/j.eurpsy.2017.02.377","volume":"2017","author":"M Gahr","year":"2017","unstructured":"Gahr M, Eller J, Connemann BJ, et al. Underreporting of adverse drug reactions: results from a survey among physicians. Eur Psychiatry. 2017;2017(41 Suppl):S369. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.02.377.","journal-title":"Eur Psychiatry"},{"key":"524_CR6","unstructured":"National Pharmacovigilance Centre, National Agency for Food and Drug Administration and Control. Safety of medicines in Nigeria: a guide for detecting and reporting adverse drug reactions. Lagos: NAFDAC-NPC-NIG; 2004."},{"key":"524_CR7","unstructured":"National Agency for Food and Drug Administration and Control Annual Reports 2002\u20132019. www.nafdac.gov.ng"},{"key":"524_CR8","unstructured":"Med Safety App | AUDA-NEPAD. https:\/\/www.nepad.org\/content\/med-safety-app Accessed 10 July 2022."},{"key":"524_CR9","unstructured":"Rayna. Med Safety App | Pharmacovigilance. PV training updates. https:\/\/www.allaboutpharmacovigilance.org\/umc-med-safety-app-an-international-mobile-tool-for-drug-safety\/. Accessed 10 July 2022"},{"key":"524_CR10","unstructured":"Med Safety App\u2014WEB-RADR. https:\/\/web-radr.eu\/mobile-apps\/med-safety\/. Accessed 10 July 2023."},{"key":"524_CR11","unstructured":"National Agency for Food and Drug Administration and Control. 2020 Med Safety Week. https:\/\/www.nafdac.gov.ng\/2020-med-safety-week\/. Accessed 10 July 2022."},{"key":"524_CR12","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2003."},{"key":"524_CR13","volume-title":"Safety monitoring of medicinal products: reporting system for the general public","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Safety monitoring of medicinal products: reporting system for the general public. Geneva: World Health Organization; 2012."},{"issue":"8","key":"524_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200810","volume":"13","author":"YK Avong","year":"2018","unstructured":"Avong YK, Jatau B, Gurumnaan R, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV\/AIDS, Tuberculosis and Malaria: a prospective cohort study. PLoS ONE. 2018;13(8): e0200810.","journal-title":"PLoS ONE"},{"issue":"5","key":"524_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"key":"524_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40264-019-00813-6","volume":"42","author":"CE Pierce","year":"2019","unstructured":"Pierce CE, de Vries ST, Bodin-Parssinen S, et al. Recommendations on the use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Saf. 2019;42:477\u201389. https:\/\/doi.org\/10.1007\/s40264-019-00813-6.","journal-title":"Drug Saf"},{"issue":"4","key":"524_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/ijp.IJP_595_18","volume":"51","author":"J Prakash","year":"2019","unstructured":"Prakash J, Joshi K, Malik D, et al. \u201cADR PvPI\u201d Android mobile app: report adverse drug reaction at any time anywhere in India. Indian J Pharmacol. 2019;51(4):236\u201342. https:\/\/doi.org\/10.4103\/ijp.IJP_595_18.","journal-title":"Indian J Pharmacol."},{"issue":"10","key":"524_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40264-018-0679-6","volume":"41","author":"I Oosterhuis","year":"2018","unstructured":"Oosterhuis I, Taavola H, Tregunno PM, et al. Characteristics, quality and contribution to signal detection of spontaneous reports of adverse drug reactions via the WEB-RADR mobile application: a descriptive cross-sectional study. Drug Saf. 2018;41(10):969\u201378. https:\/\/doi.org\/10.1007\/s40264-018-0679-6.","journal-title":"Drug Saf"},{"issue":"7","key":"524_CR19","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/ijerph19073754","volume":"19","author":"MR Salvador","year":"2022","unstructured":"Salvador MR, Monteiro C, Pereira L, Duarte AP. Quality of spontaneous reports of adverse drug reactions sent to a regional pharmacovigilance unit. Int J Environ Res Public Health. 2022;19(7):3754. https:\/\/doi.org\/10.3390\/ijerph19073754.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"524_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14740338.2019.1559812","volume":"18","author":"R Niu","year":"2019","unstructured":"Niu R, Xiang Y, Wu T, Zhi Z, et al. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China. Expert Opin Drug Saf. 2019;18(1):51\u20138. https:\/\/doi.org\/10.1080\/14740338.2019.1559812.","journal-title":"Expert Opin Drug Saf"},{"key":"524_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/2008-7802.153862","volume":"6","author":"AY Ezeuko","year":"2015","unstructured":"Ezeuko AY, Ebenebe UE, Nnebue CC, Ugoji JO. Factors associated with the reporting of adverse drug reactions by health workers in Nnewi Nigeria. Int J Prev Med. 2015;6:25. https:\/\/doi.org\/10.4103\/2008-7802.153862.","journal-title":"Int J Prev Med"},{"key":"524_CR22","unstructured":"National Primary Health Care Development Agency. The Nigerian Field Guide on Surveillance of Adverse Event Following Immunization and Response manual. National Primary Health Care Development Agency; 2018."},{"issue":"2","key":"524_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212336","volume":"14","author":"I Oh","year":"2019","unstructured":"Oh I, Baek Y, Kim H, et al. Differential completeness of spontaneous adverse event reports among hospitals\/clinics pharmacies, consumers and pharmaceutical companies in South Korea. PLoS ONE. 2019;14(2): e0212336. https:\/\/doi.org\/10.1371\/journal.pone.0212336.","journal-title":"PLoS ONE"},{"issue":"3","key":"524_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/jcpt.13086","volume":"45","author":"T Toki","year":"2020","unstructured":"Toki T, Ono S. Assessment of factors associated with completeness of spontaneous adverse event reporting in United States: a comparison between consumer reports and healthcare professional reports. J Clin Pharm Ther. 2020;45(3):462\u20139. https:\/\/doi.org\/10.1111\/jcpt.13086","journal-title":"J Clin Pharm Ther"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00524-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-024-00524-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00524-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:11:54Z","timestamp":1715973114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-024-00524-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1007\/s40290-024-00524-z","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"18 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no funding for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Uchenna Geraldine Elemuwa, Fraden Bitrus, Ibrahim Adekunle Oreagba, Adeline Ijeoma Osakwe, Abiola Sadikat Abiodun, Kenneth Onu, Asmau Abubakar, Angela E. Faniyi, Victoria Etuk, Daniel Yuah, Rametu Momodu, and Christiana Mojisola Adeyeye declare no conflicts of interest relating to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this study. Permission to carry out the study was duly obtained from the Director General of the NAFDAC","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"UGE conceived the study. UGE and FB developed the proposal for the study. IAO and CMA reviewed the proposal. DY extracted data from VigiFlow for analysis. UGE and VE analyzed the extracted data. UGE drafted the manuscript. FB, IAO, AIO, ASA, KO, AA, AEF, RM and CMA reviewed and approved the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}